Кореспондиращ автор: Жейна Чернева ( jenicherneva@yahoo.com ) Академик редактор: Иван Груев © Жейна Чернева, Радостина Чернева. Това е статия отворен достъп разпространява под условията на Creative Commons Attribution License (CC BY 4.0), която позволява използване без ограничения, разпространение, и възпроизвеждане на всякакъв носител, при условие на оригиналния автор и източник са кредитирани. Цитат:
Чернева Ж, Чернева Р (2020) Нарушения в хемостазата и терапевтично поведение при пациенти с COVID-19. Българска Кардиология 26(2): 40-45. https://doi.org/10.3897/bgcardio.26.e54113 |
Corresponding author: Zheina Cherneva ( jenicherneva@yahoo.com ) Academic editor: Ivan Gruev © Zheina Cherneva, Radostina Cherneva. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation:
Cherneva Z, Cherneva R (2020) Impairments of haemostasis and therapeutic management in patients with COVID-19. Bulgarian Cardiology 26(2): 40-45. https://doi.org/10.3897/bgcardio.26.e54113 |
The lack of prior immunity to SARS-CoV-2 coronavirus (COVID-19) infection has led to pandemic, where there is no certain management, regarding the complications of this viral illness. The lungs are the target organ for COVID-19 and patients develop acute lung injury that may progress to respiratory and multiorgan failure. Recent data shows the presence of diffuse bilateral pulmonary inflammation in COVID-19 infection. It is associated with a specific pulmonary vasculopathy, defined as pulmonary intravascular coagulopathy (PIC) that is distinct from disseminated intravascular coagulopathy (DIC). The coagulopathy in the early stages of COVID-19 is characterized by initial elevation of D-dimer and fibrin/fibrinogen degradation products, while abnormalities in prothrombin time, partial thromboplastin time and platelet counts are uncommon. That is why screening of D-dimer and fibrinogen levels, are mandatory. COVID-19-associated coagulopathy should be treated, following the guidelines for thromboembolic prophylaxis. Although D-dimer is a marker of mortality, current data does not show routine application of anticoagulants, unless otherwise clinically indicated. Bleeding in COVID-19 is uncommon, even when a laboratory constellation for DIC is present. However, if it occurs, standard guidelines for DIC management should be followed.